Galectin-1 Is a Marker but Not a Mediator of Heart Failure With Preserved Ejection Fraction
Greater circulating galectin-1 levels are associated with a higher risk of incident heart failure and higher NT-proBNP among patients with acute HFpEF. However, neither global nor myeloid deficiency of galectin-1 altered the cardiovascular phenotype in a preclinical model of HFpEF, suggesting that it is a marker but not a causal mediator of the disease.
Authors
- Deepak K. Gupta (ORCID: https://orcid.org/0000-0003-2191-3485)
- Lin Zhong (ORCID: https://orcid.org/0000-0003-2550-3758)
- David G. Harrison
- Francis J. Miller (ORCID: https://orcid.org/0000-0001-5822-0549)
- Jean W. Wassenaar (ORCID: https://orcid.org/0000-0002-2835-6338)
- Alan B. Storrow (ORCID: https://orcid.org/0000-0002-2893-808X)
- Daniel J. Fehrenbach (ORCID: https://orcid.org/0000-0003-3382-464X)
- Pranoy Sangowdar
- Quinn Wells (ORCID: https://orcid.org/0009-0009-4141-1520)
- Karen F Miller
- Sean P. Collins
- Amanda C. Doran
- C. Duncan Smart
- Megan M. Shuey
- Shi Huang
Institutions
- University of Minnesota (US)
- Vanderbilt University (US)
- VA Tennessee Valley Healthcare System (US)
- Indiana University – Purdue University Indianapolis (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Hypertension
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1161/hypertensionaha.125.26006
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 0.00